SCHEMBL6284248

SCHEMBL6284248

CC(C)[C@H](NC(=O)OC(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CMA1 P23946 13/20 0.61
ELANE P08246 1/20 0.53
CTSL P07711 1/20 0.51
CTSB P07858 1/20 0.51
CTSK P43235 1/20 0.51
ACE P12821 3/20 0.50
REN P00797 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4445986 1.00 CMA1 (0.61) CMA1ELANECTSLCTSBCTSK
SCHEMBL2162326 1.00 CMA1 (0.61) CMA1ELANECTSLCTSBCTSK
SCHEMBL8168155 1.00 CMA1 (0.61) CMA1ELANECTSLCTSBCTSK
SCHEMBL17378396 1.00 CMA1 (0.61) CMA1ELANECTSLCTSBCTSK
SCHEMBL6740347 0.92 CMA1 (0.53) CMA1ELANECTSLCTSBCTSK
SCHEMBL29787416 0.91 CMA1 (0.53) CMA1ELANECTSLCTSBCTSK
SCHEMBL13258959 0.90 CMA1 (0.51) CMA1ELANECTSLCTSBCTSK
SCHEMBL28603270 0.89 CMA1 (0.51) CMA1ELANEACEREN
SCHEMBL28603273 0.89 CMA1 (0.51) CMA1ELANEACEREN
SCHEMBL28603275 0.89 CMA1 (0.51) CMA1ELANEACEREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265480-A1 METHOD FOR DETECTION OF MICROORGANISMS NEMIS TECH AG (CH) 2023-08-24 US claimed
US-11649475-B2 Dioxetane compounds and their use for the detection of microorganisms RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2023-05-16 US claimed
US-20260027131-A1 PRODRUGS, PRODRUG COMPOSITIONS AND RELATED METHODS PRAESIDIA BIOTHERAPEUTICS INC (US) 2026-01-29 US disclosed
US-12466850-B2 Method for producing peptide compound NISSAN CHEMICAL CORPORATION (JP) 2025-11-11 US disclosed
US-12415819-B2 Cu- and Ni-catalyzed decarboxylative borylation reactions THE SCRIPPS RESEARCH INSTITUTE (US) 2025-09-16 US disclosed
CN-120202010-A Ligand-oligonucleotide conjugates and linkers for use therewith 上海京新生物医药有限公司 2025-06-24 CN disclosed
US-12240871-B2 Method for producing peptide compound NISSAN CHEMICAL CORPORATION (JP) 2025-03-04 US disclosed
CN-115210244-B Elastase inhibitor prodrug and application thereof 苏州爱科百发生物医药技术有限公司 2024-11-15 CN disclosed
CN-118772216-A 5-Fluorouracil nucleoside phosphoramidate compound and application thereof 北京深蓝泰医药科技有限公司 2024-10-15 CN disclosed
EP-4023661-B1 METHOD FOR PRODUCING PEPTIDE COMPOUND NISSAN CHEMICAL CORP (JP) 2024-09-04 EP disclosed
WO-2024083220-A1 LIGAND-OLIGONUCLEOTIDE CONJUGATE AND LINKER FOR CONJUGATE 上海京新生物医药有限公司 2024-04-25 WO disclosed
US-6008196-A AN ENZYME INHIBITORS OF HUMAN NEUTROPHIL ELASTASE HOECHST MARION ROUSSEL, INC. (US) 1999-12-28 US disclosed
EP-0763055-B1 PERFLUOROALKYL KETONE INHIBITORS OF ELASTASE AND PROCESSES FOR MAKING THE SAME MERRELL PHARMA INC (US) 1999-11-03 EP disclosed
US-5714470-A PENTAFLUORO ALKYL TERMINATED PEPTIDE DERIVATIVES; TREATMENT OF INFLAMMATORY DISEASES, EMPHYSEMA AND CHRONIC BRONCHITIS MERRELL PHARMACEUTICALS, INC. (US) 1998-02-03 US disclosed
US-4971993-A HYPOTENSIVE DIPEPTIDES DERIVATIVES AJINOMOTO CO., INC. (JP) 1990-11-20 US disclosed
US-4691007-A HUMAN LEUKOCYTE ELASTASE INHIBITORS ICI AMERICAS INC. (US) 1987-09-01 US disclosed
US-4684660-A Mercaptoacyldepeptides E. R. SQUIBB & SONS, INC. (US) 1987-08-04 US disclosed
EP-0190852-A2 Dipeptide derivatives and antihypertensive drugs containing them AJINOMOTO CO., INC. (JP) 1986-08-13 EP disclosed
US-4596789-A Pharmaceuticals ICI AMERICAS INC. (US) 1986-06-24 US disclosed
EP-0124317-A2 Proline derivatives ICI AMERICAS INC. (US) 1984-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027131-A1 PRODRUGS, PRODRUG COMPOSITIONS AND RELATED METHODS DNPEP, SLC7A1, SLC6A7 CMA1 634/4885ELANE 3218/4885CTSL 92/4885
US-11649475-B2 Dioxetane compounds and their use for the detection of microorganisms DAXX, LITAF, EDF1 CMA1 3341/4885ELANE 1504/4885CTSL 4469/4885
US-12466850-B2 Method for producing peptide compound VIP, NGLY1, NPR1 CMA1 218/4885ELANE 2125/4885CTSL 450/4885
US-12415819-B2 Cu- and Ni-catalyzed decarboxylative borylation reactions PCSK9, PCSK7, PCSK6 CMA1 14/4885ELANE 530/4885CTSL 97/4885
US-12240871-B2 Method for producing peptide compound NGLY1, NPPA, NPEPPS CMA1 550/4885ELANE 815/4885CTSL 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.